Evidence map›Paper›PMID 33163067›Full record

ArticleAfrican health sciences2020

Effect of levetiracetam drug on antioxidant and liver enzymes in epileptic patients: case-control study.

Atena Mahdavi, Amirmansour Alavi Naeini, Mohammadreza Najafi, Mohammadreza Maracy, Mohammadreza Aghaye Ghazvini

Open access · diamondAbstract read
In one paragraph

Article in African health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Levetiracetam Mechanisms of Action: From Molecules to Systems.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  6. The Influence of Oxidative Stress on Thyroid Diseases.Antioxidants (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Atena MahdaviDepartment of Community Nutrition, School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Amirmansour Alavi NaeiniDepartment of Community Nutrition, School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Mohammadreza NajafiDepartment of Neurology, School of Medicine, Isfahan University of Medical Science, Isfahan, Iran.
Mohammadreza MaracyDepartment of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.
Mohammadreza Aghaye GhazviniIsfahan Center of Health Research, National Institute of Health Research, Isfahan, Iran.
Isfahan University of Medical Sciences · IRUniversity of Isfahan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is a limited amount of data regarding levetiracetam (LEV), an antiepileptic drug.

objectiveThis study was conducted to assess the effect of LEV on antioxidant status and liver enzymes.

methodsIn this case-control study, 33 epileptic patients under treatment with LEV for at least 6 months were compared with 35 healthy subjects. We measured serum total antioxidant capacity (TAC), salivary superoxide dismutase (SOD), alanine aminoteransferase (ALT), and aspartate aminoteransferase (AST) levels in both groups. Dietary intakes were collected using a Food Frequency Questionnaire (FFQ).

resultThe level of TAC in the healthy subjects was significantly higher than it was in the patients (P=0.02), but the mean of ALT (P=0.02) and AST (P=0.03) was significantly higher in the patients in comparison with the controls. Mean salivary SOD showed no difference between the two groups. In the patients, the duration of drug use was inversely correlated with serum TAC (p=0.04) and had a direct correlation with ALT (p=0.01) and AST (p=0.03.).

conclusionThe results of our study indicated that LEV increased liver enzymes Also, treatment with this drug did not improve oxidative stress, but this could be due to the different in the dietary antioxidant intake. Routine screening of the liver and antioxidant enzymes in patients with chronic use of LEV is recommended.

Indexed as

AdultAmylasesAnticonvulsantsAntioxidantsEpilepsyFemaleHumansLevetiracetamLiverMaleMiddle AgedOxidative StressSuperoxide DismutaseAmylasesAnticonvulsantsAntioxidantsLevetiracetamSuperoxide Dismutaseantioxidantepilepsylevetiracetamliver enzymes

Identifiers

PMID33163067
PMCPMC7609075
OpenAlexW3044635985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.